Alphagan Exelon Axid Reminyl Duloxetine In fact, the only agents currently indicated for the treatment of painful dpn are duloxetine and pregabalin, and only lidocaine patches 5%, gabapentin, and pregabalin are approved for the treatment of patients with phn. Digoxin, 17 dihydrocodeine chlorpheniramine phenylephrine, 38 dihydroergotamine inj, 15 DILACOR XR, 18 DILANTIN, 15 DILANTIN INFATABS, 15 DILAUDID, 21 diltiazem, 18, 19 diltiazem ext-rel, 18, 20 diltiazem ext-rel 360 mg, 18 diltiazem ext-rel, except 360 mg, 18 DIOVAN, 19 DIOVAN HCT, 19 DIPENTUM, 29 diphenhydramine, 14, 38 DIPHENHYDRAMINE, 14, 38 diphenoxylate atropine, 27 dipivefrin, 26 DIPROLENE, 36 DIPROLENE AF, 36 dipyridamole, 16 dipyridamole ext-rel aspirin, 16 dirithromycin delayed-rel, 8 disopyramide, 17 disopyramide ext-rel, 17 DISPERMOX, 8, 12, 13 disulfiram, 25 DITROPAN, 41 DITROPAN XL, 41 divalproex sodium delayed-rel, 15, 23 dofetilide, 17 dolasetron, 28 DOLOPHINE, 21 DOMEBORO OTIC, 27 donepezil, 16 donepezil orally disintegrating tabs, 16 DONNATAL, 28 dornase alfa, 40 dorzolamide, 26 dorzolamide timolol maleate, 26 DOVONEX, 36 doxazosin, 19, 39 doxepin, 23 DOXEPIN, 23 doxepin crm, 37 doxycycline hyclate, 9, 10, 11 doxycycline monohydrate, 9, 35 DRISDOL, 39 dronabinol, 28 drospirenone EE 3 20, 31 drospirenone EE 3 30, 31 DUETACT, 30 duloxetine, 23 DUONEB, 37 DURADRIN, 15 DURAGESIC, 21 dutasteride, 41 DYAZIDE, 17 DYNABAC, 8 DYNACIN, 9 DYNACIRC CR, 18 E.E.S., 8, 12. Sir: Despite extensive clinical use of serotonin reuptake inhibitors, clomipramine, and venlafaxine1 in the treatment of obsessive-compulsive disorder OCD ; , to our knowledge there have been no reports on the use of duloxetine to treat patients with this disorder. We report the successful use of duloxetine to treat a patient with OCD. Case report. Mr. A, a 38-year-old man, had an 8-year history of OCD DSM-IV criteria ; , which began abruptly several months before his wedding and was characterized by senseless and recurrent thoughts that caused marked distress, such as, "Why do doors open and close?" and "Why does water fall out when a bucket turns upside down?" He felt compelled to repeatedly hit a door with his hands to relieve his distress; relief was only transient despite hitting the door all day long. The symptoms led to impaired work and social functioning. Treatment was begun in 1998 with clomipramine, 75 mg day, and clonazepam, 3 mg day, in addition to supportive psychotherapy. After 1 month of treatment, Mr. A had experienced significant symptomatic relief, though he had also developed loss of libido, retarded ejaculation, and anorgasmia. Clomipramine and clonazepam were discontinued, and he began treatment with paroxetine 60 mg day ; , which he did not tolerate due to severe headaches, retarded ejaculation, and anorgasmia. Mirtazapine, 30 mg day, was started to alleviate his sexual complaints. For the next 4 years, his mild obsessional thoughts did not interfere with his daily activities. Without warning, Mr. A experienced the onset of sexual obsessions in 2003 that were extremely distressing and offended his moral sense. They were characterized by a recurrent impulse to stare at attractive women. This impulse was associated with an urgent need to change his facial expression involving smiling, grimaces, or other facial contortions ; , which led to considerable anxiety. These symptoms led to social withdrawal and affected his normal routines. His antidepressant treatment was switched from mirtazapine to escitalopram 20 mg day ; . He experienced mild improvement, which allowed him to return to his routine activities. During the next 12 months, he was again bothered with persistence and worsening of his symptoms, experiencing 20 to 30 "crises" a day. With his consent, escitalopram treatment was discontinued and treatment with duloxetine 60 mg day ; was initiated. After 4 weeks and no symptom improvement, the dose was boosted to 120 mg day. One month later, Mr. A had achieved remarkable symptom improvement, reporting no subsequent obsessional "crises." During a 1-year follow-up with duloxetine maintenance, he continued to do well. According to Mr. A, this is the longest period he had ever had free of intrusive obsessional thoughts. No side effects were reported. 6-hydroxy-5-methoxy duloxetine. The comparison of the retention time, product ion mass spectrum, and NMR analysis of M10 with that of a synthesized standard confirmed this metabolite as the glucuronide conjugate of 6-hydroxy-5-methoxy duloxetine. Similar structural analyses were performed for M2, M3, M4, M8, M12 to M16, M23, and M26 and compared with synthesized standards. The retention time, product ion mass spectra, and NMR spectra were consistent with the structural assignments for these metabolites Fig. 6 ; . In addition, product ion mass spectra were obtained for M1 and M11. Both of these metabolites were not observed in urine after incubation with -glucuronidase. Comparison of the retention time and product ion mass spectra with that of the other identified metabolites and synthesized standards ; produced the structural assignment of these two conjugates of duloxetine. Discussion The biotransformation and disposition of duloxetine and its metabolites after administration of a single enteric-coated tablet containing 20.2 mg or 100.6 Ci of 14C-labeled duloxetine were characterized in this study. The mean total recovery of radioactivity was approximately 91%. The radioactivity was excreted primarily in urine 72% ; , with about 19% excreted in feces. The elimination pattern was similar between all the subjects. Figure 6 illustrates a schematic of the biotransformation pathways for duloxetine in humans. Duloxet8ne was rapidly and extensively metabolized to form multiple oxidative and conjugated metabolites. Duloxetone accounted for only a small portion approximately 3% for AUC and approximately 9% for Cmax ; of the circulating radioactivity in plasma. The peak concentrations of total radioactivity occurred at the same time as that for duloxetine, with a Tmax of approximately 6 h. The late time of peak concentrations was presumably due to the enteric coating of the. LIST A cont LOW-PROTEIN PRODUCTS cont PK Foods Aminex low-protein rusks PK Foods low-protein crispbread PK Foods low-protein pasta spirals PK Foods low-protein white sliced bread Promin low-protein cous cous Promin low-protein imitation rice Promin low-protein lasagne sheets Promin low-protein pasta alphabets, macaroni, shells, short cut spaghetti, spirals ; Promin low-protein pasta in sauce cheese and broccoli, tomato pepper and herb flavours ; Promin low-protein pastameal Promin low protein tricolour pasta alphabets, shells, spirals ; Rite-Diet low-protein baking mix. Rite-Diet low-protein flour mix Ultra low-protein canned brown bread Ultra low-protein canned white bread Ultra PKU biscuits Ultra PKU bread Ultra PKU cookies Ultra PKU flour mix Ultra PKU pizza base Ultra PKU savoy biscuits Valpiform low-protein cookies with chocolate nuggets and hazelnut flavour Valpiform low-protein savory bites herbs flavour ; Valpiform low-protein savory bites tomato flavour ; Valpiform low-protein shortbread biscuits Inherited metabolic disorders, renal or liver failure requiring a low-protein diet L-TYROSINE SUPPLEMENT FOR PHENYLKETONURIA Maternal Phenylketonurics who have low plasma tyrosine levels LUBORANT SALIVA REPLACEMENT Patients suffering from a dry mouth as a result of having or having undergone radiotherapy or sicca syndrome MAPLEFLEX UNFLAVOURED ; A leucine, isoleucine and valine free mix for use in the dietary management of MSUD approved for patients aged between 1 and 10 years. MAXIJUL LE MAXIJUL LIQUID MAXIJUL SUPER SOLUBLE Disease related malnutrion, malabsorption states or other conditions requiring fortification with a high or readily available carbohydrate supplement. MAXIPRO SUPER SOLUBLE Biochemically proven hypoproteinaemia. Not to be prescribed for any child under one year; unsuitable as a sole source of nutrition MAXISORB Biochemically proven or clinical evidence of protein deficiency, and if recommended by a renal unit. Get best content duloxetine of internet for you and cytotec. SPINE SAFETY NOTICE: Updated Prescribing Information for Cymbalta duloxetine hydrochloride ; Delayed-Release Capsules , Effexor venlafaxine hydrochloride ; Tablets and Effexor XR venlafaxine hydrochloride ; Extended- Release Capsules According to MedWatch, FDA notified healthcare professionals of revisions to the WARNINGS and PRECAUTIONS sections of the prescribing information for Cymbalta duloxetine hydrochloride ; Delayed-Release Capsules , Effexor venlafaxine hydrochloride ; Tablets and Effexor XR venlafaxine hydrochloride ; Extended- Release Capsules. The revised WARNINGS labeling indicates that the development of a potentially life-threatening serotonin syndrome may occur with Cymbalta, Effexor or Effexor XR treatment, particularly with concomitant use of serotonergic drugs including SSRIs, SNRIs and triptans for Effexor and Effexor XR, and triptans for Cymbalta ; and with drugs that impair metabolism of serotonin including MAOIs ; . Serotonin syndrome symptoms may include mental status changes eg, agitation, hallucinations, coma ; , autonomic instability eg, tachycardia, labile blood pressure, hyperthermia ; , neuromuscular aberrations eg, hyperreflexia, incoordination ; and or gastrointestinal symptoms eg, nausea, vomiting, diarrhea ; . The concomitant use of Cymbalta, Effexor or Effexor XR with MAOIs intended to treat depression is contraindicated. If concomitant treatment of Cymbalta with a 5-hydroxytryptamine receptor agonist triptan ; is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. If concomitant treatment of Effexor or Effexor XR with an SSRI, an SNRI or a 5-hydroxytryptamine receptor agonist triptan ; is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of Cymbalta with serotonin precursors such as tryptophan ; or Effexor or Effexor XR with serotonin precursors such as tryptophan supplements ; is not recommended. The revised PRECAUTIONS section for Cymbalta indicates that patients should be cautioned about the risk of serotonin syndrome with the concomitant use of Cymbalta and triptans, tramadol or other serotenergic agents. The revised PRECAUTIONS section for Effexor and Effexor XR indicates that patients should be cautioned about the risk of serotonin syndrome with concomitant use of Effexor or Effexor XR and triptans, tramadol, tryptophan supplements or other serotonergic agents. The MedWatch 2006 Safety Summary is available at : fda.gov medwatch SAFETY 2006 sep06 The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a. This weeks UK PDJ announces the grant of three UK SPCs assigned to both Chiron and Novo Nordisk. All three are based on the same patent, EP466199. They protect rurioctocog alfa, ocotocog alfa and moroctocog alfa sold under the trade names Recombinate, Kogenate and ReFacto respectively. All three SPCs have a different expiry date due to differing authorisations, the SPC covering rurioctocog alfa expires 3rd December 2007, ocotocog alfa 14th April 2009 and moroctocog alfa 10th January 2010. Also published in the UK PDJ this week was notice that the UK SPC protecting Knoll's flosequinan has now entered into force following the expiry of EP149519. This SPC will expire on 9th August 2007. This however may be of little use as flosequinan launched for the treatment of hypertension and cardiovascular disease was withdrawn in 1993 after its UK launch in 1992. Notification of two UK SPC applications were also published this week. The first attempts to protect Naemis a combination of estradiol and nomegestrol from Theramex. The application is based on EP783310 and we predict that if granted this SPC could afford protection to the product until April 2017, based on a fifteen year period from its first European marketing approval in France. The second application is from Eli Lilly and covers its dual serotonin and norepinephrine reuptake inhibitor duloxetine. This application is based on EP273658 and if granted should gain a five year term from the expiry of this patent, this would protect duloxetine until December 2012. A ruling by the United States Court of Appeals for the Federal circuit against Merck & Co was given at the end of last week. After opposition by Teva the claims of US5994329 were found to be invalid and not infringed. This patent had protected Merck's once weekly formulation of alendronic acid FOSAMAX ; . This patent was due to expire in 2018 and had gained a paediatric extension, Merck will now rely on earlier cases to protect their product cutting its US protection dramatically. DPP IV inhibitors, of which Novartis' vildagliptin is the most advanced in development for diabetes treatment, in the main contain a cyanopyrrolidine moiety. GSK appears to be pursuing an attempt to find such a compound that is sufficiently stable. A family of three PCTs was filed in June 2002 and two potential lead compounds appear to have emerged from them. This week sees an application for anhydrous, hydrated or solvated forms of 2S, 4S ; -4-fluoro-1-[4-fluoro-?- 4-fluorophenyl ; tosylate salt, whereas last October it was anhydrous crystalline forms of 2S, 4S ; -1 that was being investigated and misoprostol. FIG. 1. Chemical structure of some HIV protease inhibitors. See table 1 for the substitutions R ; . Reproduced with permission from Dorsey et al. 1994. Girish P. Joshi, M.D. BIS index value and administration of ultrashort-acting opioids e.g., remifentanil ; or adjunctive drugs e.g., beta-blockers, adenosine ; that reduce anesthetic and analgesic requirements may be more appropriate. The newer anesthetic drugs are more costly; however, early recovery from anesthesia should enable patients to meet discharge criteria and allow us to "fast-track" outpatients e.g., bypass PACU before discharge home ; resulting in cost savings. The major limitation to the fast-track process is our ability to control postoperative pain and postoperative nausea and vomiting PONV ; .3 In addition to achieving a rapid emergence from anesthesia, it is also necessary to provide adequate postoperative pain relief and prevent PONV. It is generally believed that minimally invasive surgical procedures are associated with decreased postoperative pain and or analgesic requirements. However, these procedures can still result in considerable discomfort, thereby delaying return to normal activities. Although the potential benefits of local anesthetic techniques have been recognized for a long time, these techniques are often neglected. 4 Wound infiltration and peripheral nerve blocks can provide effective analgesia in the intra- and postoperative periods. They are simple techniques with a high success rate and a low and calcitriol. Chommanard Munsumrit. The disabled workers' problems rehabilitation service needs and outcomes. Bangkok : National Institute of Development Administration, 2002. 145 p. T E19891 ; Jintana Rittharomya. The effects of health promotion program on pain level and disability in low back pain patients. Bangkok : Mahidol University, 2001. 146 p. T E17582. Definition slots layer ; : A slots layer is made of alternates of expressions, we denote the alternate operator by | pipe ; . For example, the following four expressions of date in one slot cover all possible date formats: NB month NB | NB day `, ' month NB ', ' NB month NB `, ' NB say that a slot holds if one of its expressions holds. A slot identifies relevant information or an attribute value defined by different contextual delimiters. Definition Unary operators ; : Unary operators are applied on expressions to specify occurrences or repetitions. The unary operators are: kleene * ; , optional ? ; , and one-ormore + ; . We note that the use of parentheses changes the priority. e.g. international-code ? "phone: " NB + "-" ; * Definition extraction pattern ; : An extraction pattern P over a paragraph p is a finite and unordered set of slots. |P| denotes cardinality of P i.e. number of slots ; . We mention that all slots in an extraction pattern occur without order. Furthermore, an extraction pattern of cardinality |P| has |P|! possible combinations of slots. As a result, an extraction pattern locates matching sequence of slots in any order. For example, the extraction pattern of three slots e.g. medication, dosage and frequency ; has six permutations, it locates all possible sequences and in any order of slots. Conditions on slots order: To constrain the search or define sub-sequences of some slots, we introduce the condition notation by means of forbidden and allowed. In a brief, the forbidden condition on a sub-sequence of two or more slots eliminates the sub-sequence in question from the all-possible combinations of slots. In contrast to forbidden, the keyword allowed restrains the sub sequence to appear in such order in each possible combination. Tagging relevant data: Since the extraction patterns are slightly regular expressions, it is convenient to mark up relevant data once the regular expression holds and rocaltrol. While the mechanism of action of dyloxetine is not fully known, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception may be due to increasing the activity of serotonin and norepinephrine in the central nervous system. Rather appealingly, d8loxetine is weight neutral in the majority of cases and additionally has a a generally small side effect profile, the most common side effects being somnolence , nausea and a dry mouth and carbamazepine. Duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate the activity of these chemicals in the central nervous system. News articles on duloxrtine lilly reports strong second-quarter results; raises full-year and tegretol. This issue of Clinical Cornerstone contains references to off-label unapproved uses of medications. Insulin is specifically indicated only for the treatment of hyperglycemia associated with diabetes mellitus. The above article discusses issues that are considered outside the scope of the FDAapproved indication for various drugs to treat diabetes, for example, . 5. I expect OTC medicines to be potent and carbimazole. This well designed study showed that women who stuck with their PFMT and took duloxetine gained greatest benefit. Otherwise, duloxetine was the best option for women given that many do not continue with PFMT. A cautionary note in this study is that women, unlike in many similar studies, did not gain benefit from PFMT alone this may suggest that these were inadequate.The SIGN guidelines recommend combination treatment where women request it. AW. Who.int csr disease avian influenza country cases table 2006 09 19 en inde and cefadroxil. Cymbalta duloxetine ; wellbutrin buproprion ; tricyclic class of. Duloxetine information IDSC, Monthly Economic Bulletin-"Egyptian Monthly Bulletin", vol. 11, No. 124, April 2003. Information Technology: "Llegue con Medio Tanque", May 19, 2003. Instituto Nacional de Estadsticas y Censos INDAC ; , ISSN 0327-7968, Press Release, Buenos Aires: `La Industria Farmacutica en Argentina, 1er Semester 2003", June 17, 2003. International Medical Statistics IMS ; -Geneva, Q V 2001. International Monetary Fund-Egypt: 2002 Article IV Consultation "Preliminary Assessment-Egypt Economic Situation and Prospects" ; . Discussions and duricef and duloxetine, because duloxetine stress incontinence. Discontinuation rates. Most RCT dealing with TCA in nocturnal enuresis and SSRI in PE provided safety data, but the information was often not systematically reported, especially in the older studies. No RCT were found assessing the safety profile of TCA in the treatment of retrograde ejaculation, but one non-randomised clinical trial was found to report on adverse effects [70]. The consulted FDA website contained data on safety of duloxetine, citalopram, fluoxetine, paroxetine, and sertraline. The labels of imipramine, amitriptyline or nortriptyline were not available, but the PDR website contained safety information for these TCA [71]. It is to noted that all antidepressants - including TCA carry a recently issued warning from the FDA on the increased risk of suicidal behaviour when used in paediatric patients. DISCUSSION The searches revealed more data on the SNRI duloxetine in SUI than on other amine uptake inhibitors used in the treatment of PE, retrograde ejaculation and enuresis. This is probably explained by the fact that duloxetine has been subject to a full development program quite recently in order to obtain registration for the treatment of SUI, while this has not always been the case for the other applications of antidepressants in urology. ON-LABEL USE OF AMINE UPTAKE INHIBITORS IN UROLOGY The SNRI Dulpxetine in SUI Urinary incontinence is a common and highly bothersome condition, occurring in about 35% of adult women [72, 73]. SUI is defined as the complaint of involuntary leakage on effort or exertion, or on sneezing or coughing [74]. Stress symptoms are the most common manifestation of urinary incontinence, with 37-42% of incontinent women reporting pure SUI, while 33-46% report mixed stress and urge urinary incontinence symptoms [72, 73]. SUI may be due to a hypermobile bladder neck and or urethra, urethral striated sphincter rhabdosphincter ; deficiency, or a weak or injured pelvic floor [75]. To date, SUI has been treated with lifestyle interventions such as quitting smoking, fluid management and weight loss complemented with pelvic floor muscle training or, in more severe cases, vaginal devices or surgery [76]. Until recently, no universally approved pharmacological treatment was available, although several drugs including estrogens, adrenergic receptor agonists, -adrenergic receptor antagonists, TCA, and anticholinergic agents have been tried off-label with limited, if any, success [6]. The SNRI duloxetine is the first pharmacological agent that is approved by the EMEA for the treatment of SUI [77]. SNRI have also been incorporated in the revised guidelines for the pharmacological treatment of SUI, elaborated by the 3rd International Consultation on Incontinence Monaco 2004 ; , with a grade A recommendation, which comprises the highest level of evidence i.e. high quality RCT, metaanalysis or systematic reviews of RCT ; [12]. The rationale for using an SNRI for treating SUI is based on the finding that 5-HT and NA are implicated in the. Your source for prescription drug information drug names accupril aceon almotriptan altace amerge amiodarone amnesteem atorvastatin axert banazepril biaxin bupropion caduet campath capoten captopril celexa citalopram claravis clarithromycin cordarone cylert cymbalta cytotec duloxetine duragesic effexor enalapril escitalopram faverin fevarin fluvoxamine frova gabitril galantamine gatifloxacin gefitinib imitrex iressa isotane isotrex isotretinoin lamictal lamotrigine levitra lexapro lipitor lotensin luvox mavik maxalt mifegyne mifepristone mifeprex misoprostol monopril naratriptan pacerone pemoline prinivil quinapril ramipril razadyne relpax reminyl roaccutane rosuvastatin ru-486 seropram sortis sotret sumatriptan symbyax tequin tiagabine torvast univasc vardenafil vasotec venlafaxine vivanza wellbutrin zestril zomig zyban what is caduet used for and cefdinir. In a 12-week, double blind study, cymbalta duloxetine hcl ; 60 mg once or twice daily, significantly reduced pain in more than half of women treated for fibromyalgia. You currently have 0 item in your shopping cart home vacancies special projects pharma press - about us select a drug alendronate alfuzosin anastrozole aspirin atorvastatin avaxim beclometasone bisoprolol budesonide calcipotriol candesartan celecoxib chlortalidone citalopram clopidogrel desloratadine donepezil doxazosin dukoral duloxetine dutasteride eprosartan escitalopram esomeprazole etoricoxib ezetimibe fentanyl fexofenadine finasteride fluoxetine fluticasone fluvastatin formoterol frovatriptan glibenclamide gliclazide ibuprofen inegy insulin glargine irbesartan lamotrigine lansoprazole lercanidipine levetiracetam levocetirizine losartan memantine metformin mirtazapine mometasone montelukast nateglinide nebivolol niaspan nicorandil olanzapine olmesartan omacor orlistat oseltamivir paracetamol paroxetine pegvisomant perindopril pimecrolimus pioglitazone pravastatin pregabalin prevenar quetiapine rimonabant risedronate rosuvastatin salmeterol seretide sibutramine sildenafil simvastatin strontium ranelate sumatriptan symbicort symbicort copd tacrolimus tadalafil tamsulosin telmisartan terazosin terbinafine tiotropium tolterodine twinrix typhim vi valsartan vardenafil venlafaxine viatim zolmitriptan select a disease allergic rhinitis alzheimer's disease angina arthritis asthma atherothrombosis atopic eczema back pain bipolar disorder bph breast cancer chd cholera copd depression diabetes eczema epilepsy erectile dysfunction fungal infections gord heart failure hepatitis a hepatitis c hypertension influenza irritable bowel syndrome lipid disorders menopause migraine obesity obesity and cardiometabolic risk osteoarthritis osteoporosis pain pneumococcal infections psoriasis schizophrenia thyroid disorders typhoid fever urinary incontinence weight management drugs in context the simple guides clinical trials in context other csf titles you are here publication title tolterodine in urinary incontinence - drug review reprinted from drugs in context, this thorough and independent review of the latest data on tolterodine in urinary incontinence was written by dr anna palmer and peer-reviewed by specialists in the field. Most DFID-funded SM involves supplying SM products as well as promoting behaviour change. An SM project can relate to the manufacturing sector in three ways: o As a purchaser of product - where the SMO is promoting its own branded SM product and is purchasing from a manufacturer selected on the basis of competitive tendering against a defined specification. The manufacturer may be foreign or local likely only when the product is simple [such as an ITN] or when the local market is very large [e.g. contraceptive pills in Pakistan or condoms in China] or when an international company has a local subsidiary ; . As a competitor. Competition may occur when an SM product is launched onto the market in competition with existing products which may differ in terms of price and quality. Whilst competition is healthy, concerns arise if an SM subsidy distorts the market and competes unfairly see 4.6 ; . As a business partner. This may occur when an SMO enters into an agreement with a private company in which each makes a contribution which may be an investment or may involve access to a specific technology ; towards meeting a specific objective. This is distinct from a contracting relationship and is discussed in more detail in section 5. Of pH in cell physiology; however, it has taken 40 years for their observations to be pursued in earnest. Predictably, much of the current research is being carried out with enteric bacteria, such as Salmonella typhimurium and E. coli. Earlier work with these organisms demonstrated that the prior exposure of log-phase cells to moderately low pH 6.0 to 5.5 ; induced system s ; that enhanced survival at low pH Foster, 1995 ; . Sal. typhimurium has been shown, by two-dimensional polyacrylamide gel electrophoresis 2D-PAGE ; , to synthesize key acidshock proteins ASP ; in a two-stage process called the Iacid-tolerance response' ATR ; , shown to protect the cells at pH 3.3 Foster, 1993 ; . The first stage pre-acid shock ; occurs when exponential-phase cells, exposed to mild acid pH 5.8 ; , induce an ATR-specific pH homeostatic system to augment the normal homeostasis system. A second process, or acid shock, occurs when the cells are shifted directly from neutral pH to pH 4.5 or below. While the pre-acid shock and acid shock processes are initiated by separate signals, both are required for survival of the cells at pH 3.3. Acid shock triggers the synthesis of 43 acid-shock proteins, 22 being formed in response to internal acidification, 13 induced by the external pH, while 14 are formed transiently Foster, 1993 ; . More recently, this response has been termed 'the log-phase ATR', to distinguish it from two other systems functioning in stationary-phase cells Slonczewski and Foster, 1996 ; . One is a pH-dependent 'stationary-phase ATR', a process distinct from the log-phase ATR in that it provides a higher level of resistance and involves the synthesis of fewer proteins. A third system of acid resistance is not induced by low pH, but occurs as part of a general stress resistance induced in stationary phase that is regulated by us Lange and Hengge-Aronis, 1991 ; . The other pH-induced ATRs are uS-independent. Clearly, the 2D-PAGE data demonstrate that a wide variety of genes and regulons is controlled by acid pH, and recent genetic studies have begun to determine the role played by intracellular and extracellular pH, oxidative stress, and os on the regulation of specific genes Slonczewski and Foster, 1996 ; . The general adaptive response of S. mutans to low pH indicates a significant change in a number of biochemical and growth parameters Belli and Marquis, 1991; Hamilton and Buckley, 1991 ; . Recent research has demonstrated that S. mutans responds to an 'acid shock' by the enhanced expression of 35 proteins, suggesting a complex regulatory process triggered by external acid, although the nature of many of the proteins involved is not known Svensater and Hamilton, 1997 ; . Recent genetic studies have begun to focus on individual genes that respond to external acid. For example, Yamashita and co-workers 1993 ; , using Tn916 mutagenesis, isolated a mutant of S. mutans GS5 defective in acidurance that was also sensitive to high osmolarity and high tem74, for example, duloxetine australia. Copyright © 2007 by Online.gigazu.com Inc.